Literature DB >> 19389813

Adiponectin and lipoprotein particle size.

Ram Weiss1, James D Otvos, Allan Flyvbjerg, Andre R Miserez, Jan Frystyk, Ronit Sinnreich, Jeremy D Kark.   

Abstract

OBJECTIVE: Adiponectin has been postulated to affect lipid and insulin signal transduction pathways. We evaluated the relationships of plasma adiponectin with lipoprotein mean particle size and subclass concentrations, independent of obesity and insulin sensitivity. RESEARCH DESIGN AND METHODS: A cross-sectional analysis of 884 young Israeli adults who participated in the population-based Jerusalem Lipid Research Clinic (LRC) study was conducted. Lipoprotein particle size was assessed using proton nuclear magnetic resonance.
RESULTS: In multivariable linear regression models that included sex, BMI, waist circumference, homeostasis model assessment of insulin resistance, and leptin, adiponectin was associated with mean LDL size (standardized regression coefficient B = 0.20; P < 0.001), VLDL size (B = -0.12; P < 0.001), and HDL size (B = 0.06; P = 0.013). Adiponectin was inversely related to large VLDL (P < 0.001) but positively to small VLDL (P = 0.02), inversely related to small LDL (P < 0.006) but positively to large LDL (P < 0.001), and positively related to large HDL (P < 0.001) subclass concentrations.
CONCLUSIONS: Adiponectin is favorably associated with lipoprotein particle size and subclass distribution independent of adiposity and insulin sensitivity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19389813      PMCID: PMC2699707          DOI: 10.2337/dc09-0084

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


Adiponectin is a fat-derived adipocytokine (1,2) that is strongly associated with insulin sensitivity and favorable cardiovascular outcomes. Given that insulin resistance is associated with reduced adiponectin levels (3), we hypothesized that adiponectin may have a direct role in hepatic lipoprotein metabolism. Thus, the aim of this study was to evaluate the relationships of adiponectin with lipoprotein particle size, independent of the degree of obesity and insulin sensitivity, in a population-based sample of healthy young adults.

RESEARCH DESIGN AND METHODS

The Jerusalem Lipid Research Clinic (LRC) prevalence study has previously been described (4). In a follow-up study of a sex-stratified random sample, we examined 570 men (73% response) and 314 women (68%) aged 28–32 years, as previously reported (5). Lipoprotein particle size analysis used a 400-MHz proton nuclear magnetic resonance analyzer (LipoScience, Raleigh, NC) (6). Adiponectin was analyzed using an in-house immunofluorometric assay (TRIFMA) as previously described (7). Plasma leptin and insulin concentrations were determined by radioimmunometric methods (Linco, St. Charles, MO). Sex-specific Pearson correlations, partial correlations, and multivariable linear regression modeling were used. Regression results are expressed as standardized coefficient B. Collinearity tolerances were acceptable.

RESULTS

The study population included 884 young adults (570 men and 314 women; mean ± SD age 30.1 ± 0.8 years). Men had greater BMI than women (25.1 ± 3.6 vs. 23.8 ± 3.9 kg/m2; P < 0.001), whereas women had greater adiponectin (8.9 ± 3.4 vs. 6.4 ± 2.6 mg/l; P < 0.001) and leptin concentrations (13.2 ± 8.3 vs. 5.1 ± 3.5 μg/l; P < 0.001). Adiponectin was associated with lipoprotein mean particle size in both sexes. Its strongest relation in men was an inverse association with VLDL size (r = −0.39; P < 0.001) that persisted after adjustment for BMI, waist circumference, and homeostasis model assessment of insulin resistance (HOMA-IR) (r = −0.28; P < 0.001). This relation was weaker in women (r = −0.21; P < 0.001) and was attenuated by adjustment (r = −0.12; P < 0.05). A positive association of adiponectin with HDL and LDL particle size evident in both sexes (r = ∼0.30–0.35) remained significant after adjustment. VLDL, LDL, and HDL particle sizes were introduced separately as dependent variables in backward stepwise multivariable linear regression models that included sex, BMI, waist circumference, HOMA-IR, the relevant plasma lipid or lipoprotein (triglycerides, HDL cholesterol, or LDL cholesterol), leptin, and adiponectin. Adiponectin was significantly inversely associated with VLDL size (B = −0.12; P < 0.001), whereas waist circumference (B = 0.12; P < 0.001), HOMA-IR (B = 0.09; P = 0.002), and triglycerides (B = 0.58; P < 0.001) were positively associated (model R2 = 0.57). Adiponectin was associated with larger LDL particle size (B = 0.20; P < 0.001), whereas waist circumference (B = −0.31; P < 0.001) and sex (B = −0.20; P < 0.001) were associated with smaller particle size (model R2 = 0.32). Adiponectin (B = 0.06; P = 0.013) and leptin (B = −0.10; P = 0.001) showed opposite associations with HDL particle size. HDL cholesterol was strongly associated with larger HDL particle size (B = 0.58; P < 0.001), whereas waist circumference (B = −0.14; P < 0.001), HOMA-IR (B = −0.04; P = 0.06), and male sex (B = −0.25; P < 0.001) were associated with smaller HDL particles (model R2 = 0.69). We stratified the study sample into tertiles of lipoprotein subclasses and displayed the concentration of adiponectin in each tertile of a lipoprotein subclass (i.e., large, intermediate, and small) while adjusting for sex, waist circumference, BMI, and HOMA-IR. As shown in Fig. 1A, the adiponectin concentrations differed substantially between tertiles of large VLDLs and were inversely associated with increasing concentrations of large VLDL particles (B = −0.19; P for trend < 0.001). In contrast, adiponectin was highest in the upper small VLDL tertile within each large VLDL tertile category (P for trend = 0.02). Adiponectin was highest in the upper large LDL tertile (P for trend < 0.001) (Fig. 1B). In contrast, within each large LDL tertile, adiponectin decreased consistently with increasing concentrations of small LDL particles (P for trend = 0.009). Adiponectin was positively associated with concentrations of large HDLs (P for trend < 0.001) (Fig. 1C) but was not related to small HDL particle concentrations. Thus, adiponectin concentration showed significant contrasting associations with small and large VLDL and LDL subclasses but was associated with only large HDL and not small HDL particles.
Figure 1

Adjusted plasma adiponectin concentration as a function of lipoprotein subclass tertiles adjusted for sex, waist circumference, BMI, and HOMA-IR. A: The cohort divided into tertiles of large VLDL concentrations is shown. Each of these tertiles is subdivided into tertiles of small VLDL concentrations. □, the lowest tertile (tert); ▩, the middle tertile; and ■, the upper tertile of small VLDL. B: The cohort divided into tertiles of large LDL concentrations is shown; each of these tertiles is subdivided into tertiles of small LDL concentrations. □, the lowest tertile; ▩, the middle tertile; and ■, the upper tertile of small LDL. C: The cohort divided into tertiles of large HDL concentrations is shown; each of these tertiles is subdivided into tertiles of small HDL concentrations. □, the lowest tertile; ▩, the middle tertile; and ■, the upper tertile of small HDL. *P for trend < 0.001 and 0.02 for large VLDL and small VLDL median tertile values, respectively. **P for trend < 0.001 and 0.009 for large LDL and small LDL median tertile values, respectively. ***P for trend < 0.001 for large HDL median tertile values.

Adjusted plasma adiponectin concentration as a function of lipoprotein subclass tertiles adjusted for sex, waist circumference, BMI, and HOMA-IR. A: The cohort divided into tertiles of large VLDL concentrations is shown. Each of these tertiles is subdivided into tertiles of small VLDL concentrations. □, the lowest tertile (tert); ▩, the middle tertile; and ■, the upper tertile of small VLDL. B: The cohort divided into tertiles of large LDL concentrations is shown; each of these tertiles is subdivided into tertiles of small LDL concentrations. □, the lowest tertile; ▩, the middle tertile; and ■, the upper tertile of small LDL. C: The cohort divided into tertiles of large HDL concentrations is shown; each of these tertiles is subdivided into tertiles of small HDL concentrations. □, the lowest tertile; ▩, the middle tertile; and ■, the upper tertile of small HDL. *P for trend < 0.001 and 0.02 for large VLDL and small VLDL median tertile values, respectively. **P for trend < 0.001 and 0.009 for large LDL and small LDL median tertile values, respectively. ***P for trend < 0.001 for large HDL median tertile values. We modeled adiponectin and leptin separately as dependent variables in a backward stepwise procedure that included all lipoprotein subclasses, anthropometric measures (BMI and waist circumference), and HOMA-IR. In men, adiponectin was independently inversely associated with concentrations of large VLDLs and positively associated with small VLDLs and large and intermediate HDLs. Leptin was positively associated only with small VLDLs and adiponectin after adjustment for anthropometric measures and HOMA-IR. In women, adiponectin showed an independent positive association only with large HDLs, whereas leptin was inversely associated with large VLDLs and positively with small and intermediate HDLs.

CONCLUSIONS

This analysis, in ostensibly healthy young adults, demonstrates a substantial association between plasma adiponectin and lipoprotein particle size. Adiponectin was associated with mean particle size of the three lipoprotein moieties after adjustment for measures of obesity, insulin sensitivity, leptin, and chemically measured relevant lipoprotein (triglycerides and HDL or LDL cholesterol). In addition, adiponectin was significantly linked to LDL and VLDL subclass distribution, with lower adiponectin concentrations associated with lower concentrations of large LDLs and higher concentrations of small LDLs. Such associations have previously been described in the context of insulin resistance and obesity (8); however, our findings shed further light on these relations because we show that adiponectin levels are inversely associated with the concentrations of small LDL and large VLDL particles independent of insulin sensitivity, obesity, and body fat distribution. The presence of elevated levels of small, dense LDL particles seems to be associated with increased levels of large VLDL particles and is closely associated with insulin resistance (9). Our results show that those subjects with greater concentrations of large VLDL particles had reduced adiponectin levels, whereas the opposite was found for small VLDL particles. Thus, the clustering of elevated triglycerides (as a result of increased large VLDL production) and small, dense LDL particles in the context of insulin resistance and obesity may be mediated by adiponectin that is typically reduced in this clinical setting (10,11), although the cross-sectional nature of this study cannot resolve directionality. Thus, the seemingly protective role of adiponectin against cardiovascular diseases and diabetes may not necessarily be mediated through its association with insulin sensitivity or obesity but, rather, could reflect an independent effect on lipoprotein metabolism.
  10 in total

1.  Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance.

Authors:  W Timothy Garvey; Soonho Kwon; Deyi Zheng; Sara Shaughnessy; Penny Wallace; Amy Hutto; Kimberly Pugh; Alicia J Jenkins; Richard L Klein; Youlian Liao
Journal:  Diabetes       Date:  2003-02       Impact factor: 9.461

2.  Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity.

Authors:  Y Arita; S Kihara; N Ouchi; M Takahashi; K Maeda; J Miyagawa; K Hotta; I Shimomura; T Nakamura; K Miyaoka; H Kuriyama; M Nishida; S Yamashita; K Okubo; K Matsubara; M Muraguchi; Y Ohmoto; T Funahashi; Y Matsuzawa
Journal:  Biochem Biophys Res Commun       Date:  1999-04-02       Impact factor: 3.575

3.  The "obese insulin-sensitive" adolescent: importance of adiponectin and lipid partitioning.

Authors:  Ram Weiss; Sara E Taksali; Sylvie Dufour; Catherine W Yeckel; Xenophon Papademetris; Gary Cline; William V Tamborlane; James Dziura; Gerald I Shulman; Sonia Caprio
Journal:  J Clin Endocrinol Metab       Date:  2005-03-29       Impact factor: 5.958

4.  Serum adiponectin is increased in type 1 diabetic patients with nephropathy.

Authors:  Markku Saraheimo; Carol Forsblom; Johan Fagerudd; Anna-Maija Teppo; Kim Pettersson-Fernholm; Jan Frystyk; Allan Flyvbjerg; Per-Henrik Groop
Journal:  Diabetes Care       Date:  2005-06       Impact factor: 19.112

5.  The Jerusalem Lipid Research Clinic: sampling, response and selected methodological issues.

Authors:  P E Slater; Y Friedlander; M Baras; S Harlap; S T Halfon; N A Kaufmann; S Eisenberg; A M Davies; Y Stein
Journal:  Isr J Med Sci       Date:  1982-11

6.  Taq1B CETP polymorphism, plasma CETP, lipoproteins, apolipoproteins and sex differences in a Jewish population sample characterized by low HDL-cholesterol.

Authors:  J D Kark; R Sinnreich; E Leitersdorf; Y Friedlander; S Shpitzen; G Luc
Journal:  Atherosclerosis       Date:  2000-08       Impact factor: 5.162

Review 7.  Adiponectin and adiponectin receptors.

Authors:  Takashi Kadowaki; Toshimasa Yamauchi
Journal:  Endocr Rev       Date:  2005-05       Impact factor: 19.871

8.  Insulin resistance and adiposity influence lipoprotein size and subclass concentrations. Results from the Insulin Resistance Atherosclerosis Study.

Authors:  David C Goff; Ralph B D'Agostino; Steven M Haffner; James D Otvos
Journal:  Metabolism       Date:  2005-02       Impact factor: 8.694

9.  Obesity and the metabolic syndrome in children and adolescents.

Authors:  Ram Weiss; James Dziura; Tania S Burgert; William V Tamborlane; Sara E Taksali; Catherine W Yeckel; Karin Allen; Melinda Lopes; Mary Savoye; John Morrison; Robert S Sherwin; Sonia Caprio
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

10.  AdipoQ is a novel adipose-specific gene dysregulated in obesity.

Authors:  E Hu; P Liang; B M Spiegelman
Journal:  J Biol Chem       Date:  1996-05-03       Impact factor: 5.157

  10 in total
  11 in total

1.  Pioglitazone-mediated changes in lipoprotein particle composition are predicted by changes in adiponectin level in type 2 diabetes.

Authors:  Susan Sam; Steven Haffner; Michael H Davidson; Ralph D'Agostino; Alfonso Perez; Theodore Mazzone
Journal:  J Clin Endocrinol Metab       Date:  2011-11-09       Impact factor: 5.958

2.  Change in adiponectin explains most of the change in HDL particles induced by lifestyle intervention but not metformin treatment in the Diabetes Prevention Program.

Authors:  Ronald B Goldberg; Marinella Temprosa; Lisa Mele; Trevor Orchard; Kieren Mather; George Bray; Edward Horton; Abbas Kitabchi; Jonathan Krakoff; Santica Marcovina; Leigh Perreault; Neil White
Journal:  Metabolism       Date:  2015-12-02       Impact factor: 8.694

3.  Adiponectin is associated with favorable lipoprotein profile, independent of BMI and insulin resistance, in adolescents.

Authors:  Sheela N Magge; Nicolas Stettler; Dorit Koren; Lorraine E Levitt Katz; Paul R Gallagher; Emile R Mohler; Daniel J Rader
Journal:  J Clin Endocrinol Metab       Date:  2011-03-02       Impact factor: 5.958

4.  Energy intake and leukocyte telomere length in young adults.

Authors:  Jeremy D Kark; Nehama Goldberger; Masayuki Kimura; Ronit Sinnreich; Abraham Aviv
Journal:  Am J Clin Nutr       Date:  2012-01-11       Impact factor: 7.045

5.  Serum adiponectin in relation to race-ethnicity and vascular risk factors in the Northern Manhattan Study.

Authors:  Hannah Gardener; Milita Crisby; Charlotte Sjoberg; Barry Hudson; Ronald Goldberg; Armando J Mendez; Clinton B Wright; Tatjana Rundek; Mitchell S V Elkind; Ralph L Sacco
Journal:  Metab Syndr Relat Disord       Date:  2012-11-05       Impact factor: 1.894

6.  Lifestyle and metformin treatment favorably influence lipoprotein subfraction distribution in the Diabetes Prevention Program.

Authors:  R Goldberg; M Temprosa; J Otvos; J Brunzell; S Marcovina; K Mather; R Arakaki; K Watson; E Horton; E Barrett-Connor
Journal:  J Clin Endocrinol Metab       Date:  2013-08-26       Impact factor: 5.958

7.  Epidemiologic evidence on serum adiponectin level and lipid profile.

Authors:  Vajihe Izadi; Elaheh Farabad; Leila Azadbakht
Journal:  Int J Prev Med       Date:  2013-02

Review 8.  Obesity-Related Changes in High-Density Lipoprotein Metabolism and Function.

Authors:  Julia T Stadler; Gunther Marsche
Journal:  Int J Mol Sci       Date:  2020-11-26       Impact factor: 5.923

9.  The effect of intensive glucose lowering on lipoprotein particle profiles and inflammatory markers in the Veterans Affairs Diabetes Trial (VADT).

Authors:  Juraj Koska; Aramesh Saremi; Gideon Bahn; Shizuya Yamashita; Peter D Reaven
Journal:  Diabetes Care       Date:  2013-03-27       Impact factor: 19.112

10.  Adiponectin expression protects against angiotensin II-mediated inflammation and accelerated atherosclerosis.

Authors:  Caroline M W van Stijn; Jason Kim; Grant D Barish; Uwe J F Tietge; Rajendra K Tangirala
Journal:  PLoS One       Date:  2014-01-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.